BIOCRYST PHARMACEUTICALS, INC. Basic Shares Outstanding (Weighted Average)
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Basic Shares Outstanding (Weighted Average) of 254.48 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-05
- BIOCRYST PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 254.48M shares, a 21.46% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 242.26M shares, a 15.98% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 210.98M shares, a 1.73% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 210.18M shares, a 1.58% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for fiscal 2025 was 209.89M shares, a 1.55% increase from fiscal 2024.
- BIOCRYST PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for fiscal 2024 was 206.70M shares, a 7.54% increase from fiscal 2023.
- BIOCRYST PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for fiscal 2023 was 192.20M shares, a 3.38% increase from fiscal 2022.
- BIOCRYST PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for fiscal 2022 was 185.91M shares, a 3.79% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 254.48M shares 10-Q · filed 2026-08-05 | 248.40M shares 10-Q · filed 2026-08-05 | 235.91M shares derived: average of 3 quarters · filed 2026-08-05 | 229.47M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 242.26M shares 10-Q · filed 2026-05-06 | 226.62M shares derived: average of 2 quarters · filed 2026-05-06 | 221.14M shares derived: average of 3 quarters · filed 2026-05-06 | 218.23M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | 210.98M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 210.58M shares derived: average of 2 quarters · filed 2026-02-26 | 210.22M shares derived: average of 3 quarters · filed 2026-08-05 | 209.89M shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 210.18M shares 10-Q · filed 2025-11-04 | 209.85M shares derived: average of 2 quarters · filed 2026-08-05 | 209.53M shares 10-Q · filed 2025-11-04 | 208.99M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | 209.52M shares 10-Q · filed 2026-08-05 | 209.20M shares 10-Q · filed 2026-08-05 | 208.60M shares derived: average of 3 quarters · filed 2026-08-05 | 208.17M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | 208.88M shares 10-Q · filed 2026-05-06 | 208.13M shares derived: average of 2 quarters · filed 2026-05-06 | 207.72M shares derived: average of 3 quarters · filed 2026-05-06 | 207.40M shares derived: average of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | 207.39M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 207.15M shares derived: average of 2 quarters · filed 2026-02-26 | 206.91M shares derived: average of 3 quarters · filed 2026-02-26 | 206.70M shares 10-K · filed 2026-02-26 |
| 2024-09-30 | 206.91M shares 10-Q · filed 2025-11-04 | 206.66M shares derived: average of 2 quarters · filed 2025-11-04 | 206.47M shares 10-Q · filed 2025-11-04 | 205.23M shares derived: average of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | 206.43M shares 10-Q · filed 2025-08-05 | 206.24M shares 10-Q · filed 2025-08-05 | 204.67M shares derived: average of 3 quarters · filed 2026-02-26 | 200.91M shares derived: average of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | 206.06M shares 10-Q · filed 2025-05-06 | 203.79M shares derived: average of 2 quarters · filed 2026-02-26 | 199.07M shares derived: average of 3 quarters · filed 2026-02-26 | 196.58M shares derived: average of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | 201.51M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 195.58M shares derived: average of 2 quarters · filed 2026-02-26 | 193.42M shares derived: average of 3 quarters · filed 2026-02-26 | 192.20M shares 10-K · filed 2026-02-26 |
| 2023-09-30 | 189.64M shares 10-Q · filed 2024-11-05 | 189.38M shares derived: average of 2 quarters · filed 2024-11-05 | 189.09M shares 10-Q · filed 2024-11-05 | 188.55M shares derived: average of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | 189.12M shares 10-Q · filed 2024-08-06 | 188.81M shares 10-Q · filed 2024-08-06 | 188.19M shares derived: average of 3 quarters · filed 2025-02-25 | 187.69M shares derived: average of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | 188.51M shares 10-Q · filed 2024-05-07 | 187.72M shares derived: average of 2 quarters · filed 2025-02-25 | 187.21M shares derived: average of 3 quarters · filed 2025-02-25 | 186.81M shares derived: average of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | 186.93M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | 186.56M shares derived: average of 2 quarters · filed 2025-02-25 | 186.24M shares derived: average of 3 quarters · filed 2025-02-25 | 185.91M shares 10-K · filed 2025-02-25 |
| 2022-09-30 | 186.18M shares 10-Q · filed 2023-11-08 | 185.89M shares derived: average of 2 quarters · filed 2023-11-08 | 185.57M shares 10-Q · filed 2023-11-08 | 184.64M shares derived: average of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | 185.60M shares 10-Q · filed 2023-08-07 | 185.25M shares 10-Q · filed 2023-08-07 | 184.12M shares derived: average of 3 quarters · filed 2024-02-27 | 182.87M shares derived: average of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | 184.90M shares 10-Q · filed 2023-05-08 | 183.38M shares derived: average of 2 quarters · filed 2024-02-27 | 181.96M shares derived: average of 3 quarters · filed 2024-02-27 | 181.00M shares derived: average of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | 181.87M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | 180.49M shares derived: average of 2 quarters · filed 2024-02-27 | 179.70M shares derived: average of 3 quarters · filed 2024-02-27 | 179.12M shares 10-K · filed 2024-02-27 |
| 2021-09-30 | 179.11M shares 10-Q · filed 2022-11-04 | 178.62M shares derived: average of 2 quarters · filed 2022-11-04 | 178.20M shares 10-Q · filed 2022-11-04 | |
| 2021-06-30 | 178.13M shares 10-Q · filed 2022-08-05 | 177.74M shares 10-Q · filed 2022-08-05 | ||
| 2020-12-31 | 167.27M shares 10-K · filed 2023-02-27 | |||
| 2016-06-30 | 73.69M shares 10-Q · filed 2016-08-08 | 73.65M shares 10-Q · filed 2016-08-08 | ||
| 2015-06-30 | 72.64M shares 10-Q · filed 2016-08-08 | 72.49M shares 10-Q · filed 2016-08-08 | ||
| 2014-06-30 | 63.65M shares 10-Q · filed 2015-08-07 | 61.63M shares 10-Q · filed 2015-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |